A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

计划入组 1,740 人 · 首次发布于 2026 年 7 月 14 日

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

计划入组 380 人 · 首次发布于 2026 年 7 月 15 日

A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)

计划入组 124 人 · 首次发布于 2024 年 8 月 28 日

Metabolic dysfunction-associated steatohepatitis(Cellarity)

siRNA therapy (sc, metabolic dysfunction-associated steatohepatitis)

undisclosed program

METABOLIC THERAPY, INC.

United States

Metabolic Technologies, Inc.

United States

Associated Capital

United States

Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion

AI-Based Pathology Tool Validated for Scoring Metabolic Dysfunction-Associated Steatohepatitis

Multi-biotics Enhance Lenvatinib Sensitivity in MASH-Related HCC Organoids